Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HLA-DRB1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HLA-DRB1/HLA-DRA Heterodimer (e.g., *04:01, *15:01, *03:01 alleles) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View HLA-DRB1 Products |
| Gene Delivery | HLA-DRB1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based antigen presentation assays. |
View HLA-DRB1 Products |
| Benchmark Ab | Anti-HLA-DR Recombinant Antibody (Clone L243) Recombinant positive control for blocking and conformation verification. |
View HLA-DRB1 Products |
| Validator | HLA-DRB1 siRNA Set For knockdown verification in functional assays. |
View HLA-DRB1 Products |
| Related Target A | HLA-DRA Required pairing partner to form functional MHC Class II heterodimers. |
View HLA-DRA Products |
| Related Target B | LAG3 Key immune checkpoint receptor that binds directly to MHC Class II molecules. |
View LAG3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Allele-specific cross-reactivity profiling | Multiple HLA-DRB1 allele proteins (*04:01, *15:01, *03:01) available with >95% purity. |
| Conformation-dependent binding assays | HEK293 expressed heterodimers ensuring native folding and post-translational modifications. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live HLA-DRB1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HLA-DRB1 therapeutics is intensifying, with major players shifting focus from traditional broad immunosuppressive mAbs to allele-specific tolerogenic therapies and TCR-like therapeutics. As first-generation therapies reach the clinic, the next wave of R&D is targeting antigen-specific TCR-T cell therapies and peptide-MHC (pMHC) directed biologics to treat autoimmune diseases like rheumatoid arthritis and multiple sclerosis without compromising systemic immunity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Tolerogenic Peptides / pMHC | Anokion, Cour Pharmaceutical | Multiple Sclerosis, Celiac Disease | Peptide-binding affinity assays (Need highly stable HLA-DRB1/DRA heterodimers) |
| TCR-T / TCR-like mAbs | Immunocore, Adaptimmune | Oncology, Autoimmune | Specificity verification (Need a panel of mutant and wild-type HLA-DRB1 alleles) |
| Monoclonal Antibodies | Immutep, Bristol Myers Squibb | Cancer Immunotherapy (LAG3/MHC-II block) | Blocking assays (Need high-purity, sequence-verified HLA-DRB1 protein) |